EMA Recommends Extending Indications for Durvalumab By Ogkologos - July 17, 2025 636 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns a neoadjuvant and adjuvant treatment of patients with muscle invasive bladder cancer Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR New on NCI’s Websites for August 2024 August 16, 2024 Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma March 30, 2022 FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 NCI and FDA Address Common Concerns: A Win–Win for Making Progress... September 17, 2018 Load more HOT NEWS Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced... How “the most advanced machine learning approach” is finding new cancer-causing... A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer
